Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
NCT ID: NCT00278278
Last Updated: 2013-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
150 participants
INTERVENTIONAL
2003-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase III trial is studying giving methotrexate together with combination chemotherapy and radiation therapy to see how well it works compared to combination chemotherapy and radiation therapy alone in treating young patients with newly diagnosed gliomas.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Determine if the addition of high-dose methotrexate prior to standard treatment improves survival of patients with malignant high-grade glioma or diffuse intrinsic pontine glioma as compared to standard treatment only.
Secondary
* Determine if the addition of high-dose methotrexate, as compared to standard treatment only, improves the tumor response of these patients.
* Determine if high-dose methotrexate, compared to standard treatment only, improves the progression-free or event-free survival of these patients.
* Determine if high-dose methotrexate, as compared to standard treatment only, improves the health status (quality of life) of these patients.
* Determine if consolidation therapy improves the overall, progression-free, or event-free survival rates as compared to the historical control group.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to tumor location includes pons (yes vs no) and complete or nearly complete resection (yes vs no).
* Surgery: All patients are encouraged to undergo radical resection of the tumor to reduce intracranial pressure, remove as much tumor tissue as possible, and obtain tumor tissue for histological diagnosis. Within 14 days after surgery, patients proceed to induction chemotherapy.
* Induction therapy: Patients are randomized to 1 of 2 treatment arms.
* Arm I:
* High-dose methotrexate with leucovorin calcium: Patients receive high-dose methotrexate IV over 24 hours on days 1 and 15 and leucovorin calcium IV every 6 hours on days 2-3 an 16-17. Patients proceed to chemoradiotherapy 4 weeks later.
* Chemoradiotherapy (course 1): Patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks. Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Patients proceed to course 2 of chemoradiotherapy 7 days prior to completion of radiotherapy.
* Chemoradiotherapy (course 2): Patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5. Patients proceed to consolidation chemotherapy 4 weeks later.
* Arm II: Patients receive chemoradiotherapy courses 1 and 2 as in arm I and proceed to consolidation chemotherapy 4 weeks later.
* Consolidation chemotherapy: Patients receive vincristine IV on days 1, 8, and 15, oral lomustine once on day 2, and oral prednisone once daily on days 1-17. Treatment repeats every 6 weeks for up to 8 courses.
Quality of life is assessed 1 week after surgery, after completion of chemoradiotherapy, at 1, 4, and 13 months after completion of consolidation chemotherapy, and then annually for 3 years.
After completion of study treatment, patients are followed periodically for 3 years.
PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Patients receive high-dose methotrexate IV over 24 hours on days 1 and 15 and leucovorin calcium IV every 6 hours on days 2-3 an 16-17. Four weeks later, patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.
Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5.
cisplatin
Given IV
etoposide
Given IV
ifosfamide
Given IV
lomustine
Given IV
methotrexate
Given IV
prednisone
Given IV
vincristine sulfate
Given IV
Arm II
Patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.
Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5.
cisplatin
Given IV
etoposide
Given IV
ifosfamide
Given IV
lomustine
Given IV
prednisone
Given IV
vincristine sulfate
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cisplatin
Given IV
etoposide
Given IV
ifosfamide
Given IV
lomustine
Given IV
methotrexate
Given IV
prednisone
Given IV
vincristine sulfate
Given IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosed tumors of the brain or spinal cord, meeting one of the following criteria:
* Histologically\* confirmed diagnosis of 1 of the following high-grade gliomas:
* Glioblastoma (WHOº IV)
* Anaplastic astrocytoma (WHOº III)
* Gliosarcoma (WHOº III or IV)
* Anaplastic oligo-astrocytoma NOTE: \*Histological requirement may be waived for other types of brainstem glioma
* Radiologically proven diffuse intrinsic pontine glioma
* Second malignancy or disseminate metastases or multifocal tumors are allowed if the field of irradiation is not too large
* No diffuse metastases making craniospinal irradiation necessary
PATIENT CHARACTERISTICS:
* No cardiorespiratory insufficiency requiring medical respiration
* No low blood pressure requiring systemic catecholamines
* No severe neurological damage (e.g., coma)
* No tetraplegia without possibility to communicate
* No other poor clinical condition
* Not pregnant
* Fertile patients must use effective contraception
* No hypersensitivity to methotrexate, cisplatin, vincristine, lomustine, or ifosfamide
* No other malignancy preceding radiotherapy that does not allow further radiation
PRIOR CONCURRENT THERAPY:
* No prior chemotherapy for brain tumor
* The following prior therapies are allowed:
* Mistletoe
* H15 (extract of Boswellia serrata)
* Homeopathy therapy with dilution \> 4D
* Alternative medicine without proven efficacy
* No prior radiotherapy for brain tumor
* No concurrent alcohol or tobacco consumption
* No concurrent participation in another study
3 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Society for Pediatric Oncology and Hematology GPOH gGmbH
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Children's Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christoph Kramm, MD
Role: STUDY_CHAIR
University Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M. D. Anderson Cancer Center at University of Texas
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wolff JE, Kortmann RD, Wolff B, Pietsch T, Peters O, Schmid HJ, Rutkowski S, Warmuth-Metz M, Kramm C. High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study. J Neurooncol. 2011 May;102(3):433-42. doi: 10.1007/s11060-010-0334-2. Epub 2010 Aug 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GPOH-HIT-GBM-D
Identifier Type: -
Identifier Source: secondary_id
EU-205100
Identifier Type: -
Identifier Source: secondary_id
CDR0000454723
Identifier Type: -
Identifier Source: org_study_id